ai-enabled-heart-diagnostics-put-heartflow-(htfl)-in-the-spotlight

AI-Enabled Heart Diagnostics Put HeartFlow (HTFL) in the Spotlight

Business

2 min read

HeartFlow, Inc. (NASDAQ:HTFL) is one of the AI Stocks to Watch Out For in 2025On September 2, JPMorgan analyst Robbie Marcus initiates coverage on the stock with an Overweight rating and a price target of $36.00.

The firm believes that Heartflow is “one of the clearest and most pioneering downstream beneficiaries of the AI revolution in the healthcare sector.”

The company is using artificial intelligence in healthcare to help diagnose heart disease. Through their technology, doctors can gain better insights of a patient’s heart while reducing costs and improving workflow.

Jirsak/Shutterstock.com

JP Morgan believes that even though investors are rightly focused on the hardware, data, and infrastructure that’s driving modern artificial intelligence, HTFL stands out as a clear and pioneering downstream beneficiary of the AI revolution in healthcare.

“The company operates at the unique intersection of regulated healthcare and technology through its novel, AI-enabled, diagnostic software for coronary artery disease (CAD). The novel platform uses AI and advanced computational fluid dynamics to create a personalized 3D model of a patient’s heart based off of a single coronary computed tomography angiography (CCTA). Heartflow is one of the first MedTech companies to offer a clinically meaningful and reimbursed product that leverages modern day computing power and machine learning/AI to address a clinical unmet need in coronary artery disease (CAD), while simultaneously offering the potential to streamline procedural workflow and lower overall cost of care. As one of the few pure-play software MedTech businesses, Heartflow benefits from a capital-light business model, an excellent gross margin profile, clinical/regulatory moat with healthy reimbursement, and a highly differentiated diagnostic solution in a large, untapped market.”

HeartFlow, Inc. (NASDAQ:HTFL) is a medical technology company.

While we acknowledge the potential of HTFL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Must-Watch AI Stocks on Wall Street and 10 AI Stocks Investors Are Watching Closely.

Disclosure: None.